We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.46 | -1.50% | 95.81 | 97.83 | 97.11 | 97.63 | 1,180,808 | 01:00:00 |
From May 2019 to May 2024
By Brian Blackstone and Donato Paolo Mancini
ZURICH--Swiss drugmaker Novartis AG (NOVN.EB) won't face criminal proceedings over $1.2 million in payments it made to a company owned by U.S. President Donald Trump's longtime personal lawyer, Michael Cohen, the Swiss attorney general's office said Wednesday.
"Following a detailed analysis, the [Office of the Attorney General of Switzerland] concluded that there was insufficient suspicion to justify opening criminal proceedings," it said in a statement.
Novartis declined to comment.
In its statement Wednesday, the attorney general's office said its examination "failed to confirm that there was sufficient suspicion in relation to the offence of bribery of foreign public officials."
"There was neither sufficient suspicion that the payments were made to a foreign public official nor that there was any link between the payments and any official act," it said.
Write to Brian Blackstone at brian.blackstone@wsj.com and Donato Paolo Mancini donatopaolo.mancini@wsj.com
(END) Dow Jones Newswires
June 06, 2018 09:32 ET (13:32 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
